(S1 (S (S (VP (VP (VBD Suppressed) (NP (NN transformation))) (CC and) (VP (VBD induced) (NP (NP (NN differentiation)) (PP (IN of) (NP (JJ HER-2/neu-overexpressing) (NN breast) (NN cancer) (NNS cells))) (PP (IN by) (NP (NN emodin))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NP (NN amplification)) (CC and) (NP (NN overexpression))) (PP (IN of) (NP (DT the) (NN HER-2/neu) (NN proto-oncogene))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ encodes) (NP (DT the) (NN tyrosine) (NN kinase) (NN receptor) (NN p185neu))))) (, ,)) (VP (VP (VBP have) (VP (VBN been) (VP (VBN observed) (ADVP (RB frequently)) (PP (IN in) (NP (NP (NNS tumors)) (PP (IN from) (NP (JJ human) (NN breast) (NN cancer) (NNS patients)))))))) (CC and) (VP (VBP are) (VP (VBN correlated) (PP (IN with) (NP (JJ poor) (NN prognosis))))))) (. .)))
(S1 (S (S (VP (TO To) (VP (VB explore) (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (NP (NN chemotherapy)) (VP (VBN directed) (PP (IN at) (NP (NP (DT the) (NN tyrosine) (NN kinase)) (PP (IN of) (NP (NN p185neu)))))))))))) (, ,) (S (NP (PRP we)) (VP (VBP have) (VP (VBN found) (SBAR (IN that) (S (NP (NP (NP (NN emodin)) (PRN (-LRB- -LRB-) (NP (NN 3-methyl-1,6,8-trihydroxyanthraquinone)) (-RRB- -RRB-))) (, ,) (NP (DT a) (NN tyrosine) (NN kinase) (NN inhibitor)) (, ,)) (VP (VBZ suppresses) (NP (NP (NP (NP (NN autophosphorylation)) (CC and) (NP (NN transphosphorylation))) (NNS activities)) (PP (IN of) (NP (NN HER-2/neu) (NN tyrosine) (NN kinase)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (NN tyrosine) (NN hypophosphorylation)) (PP (IN of) (NP (NN p185neu))) (PP (IN in) (NP (JJ HER-2/neu-overexpressing) (NN breast) (NN cancer) (NNS cells))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Emodin)) (, ,) (PP (IN at) (NP (NP (DT a) (JJ 40-microM) (NN concentration)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBD repressed) (NP (NP (NN tyrosine) (NN kinase)) (PP (IN of) (NP (NN p185neu))))))))) (, ,)) (ADVP (RB efficiently)) (VP (VBD inhibited) (NP (CC both) (NP (NN anchorage-dependent)) (CC and) (NP (NP (JJ anchorage-independent) (NN growth)) (PP (IN of) (NP (JJ HER-2/neu-overexpressing) (NN breast) (NN cancer) (NNS cells))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (DT the) (NN inhibition)) (VP (VBD was) (ADJP (ADVP (RB much) (RBR less)) (JJ effective) (PP (IN for) (NP (NP (DT those) (NNS cells)) (VP (VBG expressing) (NP (NP (JJ basal) (NNS levels)) (PP (IN of) (NP (NN p185neu)))) (PP (IN under) (NP (DT the) (JJ same) (NNS conditions))))))))) (. .)))
(S1 (S (S (NP (NN Emodin)) (ADVP (RB also)) (VP (VBD induced) (NP (NP (NN differentiation)) (PP (IN of) (NP (JJ HER-2/neu-overexpressing) (NN breast) (NN cancer) (NNS cells)))) (PP (PP (IN by) (S (VP (VBG exhibiting) (NP (NP (DT a) (JJ morphological) (NN maturation) (NN property)) (PP (IN of) (NP (NP (JJ large) (NN lacy) (NNS nuclei)) (VP (VBN surrounded) (PP (IN by) (NP (JJ sizable) (NN flat) (NN cytoplasm)))))))))) (CC and) (PP (IN by) (S (VP (VBG showing) (NP (NP (DT a) (JJ measurable) (NN production)) (PP (IN of) (NP (JJ large) (NN lipid) (NNS droplets))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (NP (DT a) (NN marker)) (PP (IN of) (NP (JJ mature) (NN breast) (NNS cells)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (PRP$ our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN emodin)) (VP (VP (VBZ inhibits) (NP (NP (NN HER-2/neu) (NN tyrosine) (NN kinase)) (NN activity))) (CC and) (VP (ADVP (RB preferentially)) (VP (VP (VBZ suppresses) (NP (NN growth))) (CC and) (VP (VBZ induces) (NP (NP (NN differentiation)) (PP (IN of) (NP (JJ HER-2/neu-overexpressing) (NN cancer) (NNS cells)))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (MD may) (VP (VB have) (NP (JJ chemotherapeutic) (NNS implications)) (PP (IN for) (S (VP (VBG using) (NP (NP (NN emodin)) (PP (TO to) (NP (NN target) (JJ HER-2/neu-overexpressing) (NN cancer) (NNS cells)))))))))) (. .)))
